About Codexis (NASDAQ:CDXS)
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Industry, Sector and Symbol:
- Sector: Industrial Products
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CDXS
- CUSIP: 19200510
- Web: www.codexis.com
- Market Cap: $352.77 million
- Outstanding Shares: 48,324,000
- 50 Day Moving Avg: $6.41
- 200 Day Moving Avg: $5.29
- 52 Week Range: $3.60 - $7.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -40.56
- P/E Growth: -1.13
- Annual Revenue: $43.16 million
- Price / Sales: 8.17
- Book Value: $0.63 per share
- Price / Book: 11.59
- EBITDA: ($15,160,000.00)
- Net Margins: -40.70%
- Return on Equity: -83.39%
- Return on Assets: -45.44%
- Current Ratio: 3.06%
- Quick Ratio: 2.99%
- Average Volume: 170,002 shs.
- Beta: -1.43
- Short Ratio: 14.32
Frequently Asked Questions for Codexis (NASDAQ:CDXS)
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $10.30 million for the quarter, compared to analyst estimates of $9.61 million. Codexis had a negative net margin of 40.70% and a negative return on equity of 83.39%. The company's quarterly revenue was down 35.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 earnings per share. View Codexis' Earnings History.
When will Codexis make its next earnings announcement?
Where is Codexis' stock going? Where will Codexis' stock price be in 2017?
4 brokerages have issued 1-year target prices for Codexis' stock. Their predictions range from $5.50 to $11.00. On average, they anticipate Codexis' stock price to reach $7.81 in the next twelve months. View Analyst Ratings for Codexis.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), BeyondSpring (BYSI), WAVE Life Sciences (WVE), Voyager Therapeutics (VYGR), Celyad SA (CYAD), ImmunoGen (IMGN), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Mesoblast Limited (MESO), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS), Agenus (AGEN), Kala Pharmaceuticals (KALA), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE) and Arbutus Biopharma Corporation (ABUS).
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Bernard J. Kelley, Chairman of the Board
- John J. Nicols, President, Chief Executive Officer, Director
- Gordon T. Sangster, Chief Financial Officer, Senior Vice President
- Douglas T. Sheehy J.D., Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
- Michael Douglas Arthur Aldridge, Senior Vice President - Corporate & Strategic Development
- James Lalonde, Senior Vice President, Research & Development
- Thomas R. Baruch J.D., Chairman Emeritus
- Pam P. Cheng, Director
- Kathleen Sereda Glaub, Director
- Patrick Y. Yang, Director
Who owns Codexis stock?
Codexis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
VIVO VENTURES VII, LLC
(6.30%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.
How do I buy Codexis stock?
Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Codexis' stock price today?
MarketBeat Community Rating for Codexis (NASDAQ CDXS)MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Codexis stock can currently be purchased for approximately $7.30.
Consensus Ratings for Codexis (NASDAQ:CDXS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$7.81 (7.02% upside)|Consensus Price Target History for Codexis (NASDAQ:CDXS)
Analysts' Ratings History for Codexis (NASDAQ:CDXS)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/13/2017||Jefferies Group LLC||Boost Price Target||Buy||$9.00 -> $11.00||N/A|
|10/13/2017||HC Wainwright||Boost Price Target||Buy -> Buy||$8.00 -> $8.50||N/A|
|1/26/2017||First Analysis||Downgrade||Overweight -> Equal Weight||$5.50||N/A|
|1/4/2017||Ladenburg Thalmann Financial Services||Upgrade||Neutral -> Buy||$6.25||N/A|
Earnings History for Codexis (NASDAQ:CDXS)Earnings History by Quarter for Codexis (NASDAQ CDXS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.13)||($0.13)||$9.61 million||$10.30 million||View||Listen|
|5/9/2017||Q1 2017||($0.15)||($0.18)||$9.23 million||$7.97 million||View||Listen|
|3/9/2017||Q4 2016||($0.11)||($0.12)||$9.15 million||$10.00 million||View||Listen|
|11/8/2016||Q3||($0.14)||$0.06||$7.41 million||$14.90 million||View||Listen|
|8/9/2016||Q216||$0.03||$0.12||$15.10 million||$16.00 million||View||Listen|
|5/9/2016||Q1||($0.15)||($0.11)||$7.49 million||$8.00 million||View||Listen|
|3/3/2016||Q4||($0.04)||$0.02||$11.63 million||$11.60 million||View||N/A|
|11/4/2015||Q315||($0.11)||$0.13||$8.85 million||$17.40 million||View||Listen|
|8/11/2015||Q215||($0.14)||($0.14)||$7.34 million||$6.02 million||View||Listen|
|5/7/2015||Q115||($0.12)||($0.14)||$8.00 million||$6.80 million||View||Listen|
|3/3/2015||Q414||$0.01||$0.07||$13.30 million||$14.20 million||View||Listen|
|11/4/2014||Q314||($0.06)||($0.05)||$9.00 million||$7.47 million||View||Listen|
|8/6/2014||Q214||($0.15)||($0.22)||$8.50 million||$6.60 million||View||Listen|
|5/7/2014||Q114||($0.10)||($0.17)||$10.00 million||$7.10 million||View||Listen|
|3/11/2014||Q413||($0.21)||($0.26)||$10.00 million||$9.50 million||View||Listen|
|11/12/2013||Q313||($0.31)||($0.24)||$8.50 million||$3.90 million||View||Listen|
|8/9/2013||Q2 2013||($0.28)||($0.33)||$9.00 million||$6.97 million||View||Listen|
|5/7/2013||Q1 2013||($0.36)||($0.25)||$7.63 million||$11.48 million||View||Listen|
|2/27/2013||Q4 2012||($0.34)||($0.41)||$9.33 million||$7.90 million||View||Listen|
|11/7/2012||Q312||($0.15)||($0.06)||$25.88 million||$26.34 million||View||N/A|
Earnings Estimates for Codexis (NASDAQ:CDXS)
2017 EPS Consensus Estimate: ($0.35)
2018 EPS Consensus Estimate: ($0.13)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Codexis (NASDAQ:CDXS)
Insider Ownership Percentage: 9.80%Insider Trades by Quarter for Codexis (NASDAQ:CDXS)
Institutional Ownership Percentage: 63.62%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/14/2017||Ventures Vii Affiliates F Vivo||Major Shareholder||Sell||1,060,000||$5.78||$6,126,800.00|| |
|11/15/2016||Patrick Y Yang||Director||Buy||10,000||$4.83||$48,300.00|| |
|9/8/2016||Ventures Fund Vii L.P. Vivo||Major Shareholder||Sell||111,600||$4.25||$474,300.00|| |
|8/29/2016||Dennis P Wolf||Director||Sell||18,000||$4.22||$75,960.00|| |
|8/24/2016||Bernard J Kelley||Director||Sell||12,643||$4.26||$53,859.18|| |
|8/16/2016||Ventures Fund Vii L.P. Vivo||Major Shareholder||Sell||86,894||$4.25||$369,299.50|| |
|8/15/2016||Vivo Ventures Vii, Llc||Major Shareholder||Sell||50,000||$4.27||$213,500.00|| |
|8/4/2016||Ventures Fund Vii L.P. Vivo||Major Shareholder||Sell||80,000||$4.22||$337,600.00|| |
|11/11/2015||James Lalonde||SVP||Sell||9,441||$3.52||$33,232.32|| |
|9/11/2015||Patrick Y Yang||Director||Buy||10,000||$3.47||$34,700.00|| |
|9/10/2015||Bernard J. Kelley||Director||Sell||5,200||$3.45||$17,940.00|| |
|8/24/2015||Patrick Y Yang||Director||Buy||10,000||$3.84||$38,400.00|| |
|8/14/2015||Patrick Y Yang||Director||Buy||20,000||$3.97||$79,400.00|| |
|6/15/2015||Dennis P Wolf||Director||Sell||35,416||$4.10||$145,205.60|| |
|11/18/2014||Patrick Y Yang||Director||Buy||20,000||$2.35||$47,000.00|| |
|11/17/2014||Patrick Y Yang||Director||Buy||20,000||$2.34||$46,800.00|| |
|8/12/2014||Patrick Y Yang||Director||Buy||60,000||$2.22||$133,200.00|| |
|3/8/2013||John J Nicols||CEO||Buy||27,000||$2.42||$65,340.00|| |
|3/7/2013||John J Nicols||CEO||Buy||54,000||$2.22||$119,880.00|| |
|3/4/2013||David D O'toole||CFO||Buy||10,000||$2.02||$20,200.00|| |
|11/12/2012||David D O'toole||CFO||Buy||5,000||$2.20||$11,000.00|| |
|9/14/2012||David D O'toole||CFO||Buy||5,000||$2.78||$13,900.00|| |
|9/14/2012||Douglas T Sheehy||SVP||Sell||3,800||$2.76||$10,488.00|| |
Headline Trends for Codexis (NASDAQ:CDXS)
Latest Headlines for Codexis (NASDAQ:CDXS)
Loading headlines, please wait.
Codexis (CDXS) Chart for Sunday, October, 22, 2017